Clinical trials: Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
- Condition Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
- Funder type Industry (pharma, biotech, devices)
Lower Urinary Tract Symptoms, Prostatic Hyperplasia
Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
The goal of this clinical trial is to learn if Longidaze works to treat lower urinary tract symptoms in adult males with benign prostatic hyperplasia. It will also learn about the safety of Longidaze.
- Trial name
- ADAM (NCT06568718)
- Testing
- bovhyaluronidase azoximer, tamsulosin
- Where
- 3 sites in Russia
- Volunteers
- 229 people
- Sponsor
- NPO Petrovax
Nocturia, Benign Prostatic Hyperplasia
Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia
The objective of this study is to determine safety and efficacy of silodosin, which is a treatment for benign prostatic hyperplasia with high selectivity to α1A-receptor, on patients with benign prostatic hyperplasia accompanied…
- Trial name
- BPH (NCT02106182)
- Testing
- Silodosin, Laboratory tests, 3-days voiding diary
- Where
- 6 sites in South Korea
- Volunteers
- 135 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System
To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
- Trial name
- CV (NCT02029560)
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- JW Pharmaceutical
Benign Prostatic Hyperplasia
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the…
- Trial name
- RAPID-III (NCT06849258)
- Testing
- FloStent
- Where
- 20 sites in United States, Australia
- Volunteers
- 215 people
- Sponsor
- Rivermark Medical
Prostatism, Erectile Dysfunction
Study of Dr. Pyke's Supplement for Stream (S4S) in Men With Prostatism and ED
This is the first clinical trial of Dr. Pyke's Supplement for Stream (S4S), a proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3, to investigate its effects on prostatism and erections…
- Trial name
- S4S4BPH/ED (NCT03681392)
- Testing
- Dr. Pyke's Supplement for Stream (S4S)
- Sponsor
- Robert E. Pyke
Hyperplasia
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
The purpose of this study is to evaluate the effectiveness and safety of Naftopidil and Tamsulosin in the treatment of lower urinary tract symptoms through a comparative study of patients with benign prostatic hyperplasia.
- Trial name
- NCT01203371
- Testing
- Naftopidil, Tamsulosin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
Impotence
Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH)
The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.
- Trial name
- NCT00143221
- Testing
- Viagra
- Volunteers
- 350 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Nocturia
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.
- Trial name
- EQUINOC (NCT02637960)
- Testing
- Fedovapagon 2 mg
- Where
- 48 sites in United States
- Volunteers
- 432 people
- Sponsor
- Vantia Ltd
Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
Irreversible Electroporation (IRE) for the Treatment of Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of using Irreversible Electroporation (IRE) for the treatment of symptomatic benign prostatic hyperplasia (BPH).
- Trial name
- RELIEF (NCT07640776)
- Testing
- Irreversible Electroporation
- Volunteers
- 40 people
- Sponsor
- Angiodynamics, Inc.
Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation
This is an open-label, single-arm, prospective interventional study to assess the tolerability and efficacy of Harnalidge® OCAS® 0.4 mg in Taiwan patients who are unsatisfied with tamsulosin 0.2 mg for the treatment of lower…
- Trial name
- NCT02180789
- Testing
- Tamsulosin OCAS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms
Clinical study to examine the safety, tolerability and efficacy of long-term combination therapy of tamsulosin and solifenacin in the treatment of males with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- Neptune II (NCT01021332)
- Testing
- tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- Where
- 70 sites in Austria, Belarus and 9 more
- Volunteers
- 1,067 people
- Sponsor
- Astellas Pharma Europe B.V.
Lower Urinary Tract Symptoms (LUTS)
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic…
- Trial name
- DELUTS (NCT00947882)
- Testing
- Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 404 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Hyperplasia
Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.
This is a 12 week study in which different doses and formulations of UK-369,003 will be administered to patients with a diagnosis of enlarged prostate.
- Trial name
- NCT00457457
- Testing
- Tamsulosin, UK-369,003
- Where
- 46 sites in Australia, Belgium and 13 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with…
- Trial name
- NCT00409357
- Testing
- SL77.0499-10 (alfuzosin hydrochloride)
- Where
- Japan
- Volunteers
- 473 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker.
- Trial name
- NCT02431754
- Testing
- Tadalafil, Alpha1 Blocker
- Where
- 9 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study investigates the safety and efficacy of a photosensitive drug (talaporfin sodium) activated by an intraurethrally placed drug-activating device.
- Trial name
- NCT02326454
- Testing
- talaporfin sodium, Saline, Drug Activator 100 J/cm
- Where
- 41 sites in United States
- Volunteers
- 225 people
- Sponsor
- Light Sciences Oncology
Prostatic Hyperplasia, Benign
Efficacy/ Safety of Product DNN.65.21.005 in Patients With Benign Prostatic Hyperplasia
To evaluate the safety and efficacy of DNN.65.21.005 versus Combodart® in the treatment of benign prostatic hyperplasia
- Trial name
- NICCOLO (NCT07270432)
- Testing
- Product DNN.65.21.005, Combodart®
- Volunteers
- 218 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Benign Prostatic Hypertrophy
The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy…
- Trial name
- NCT00427219
- Testing
- Ozarelix
- Where
- 13 sites in United States
- Volunteers
- 74 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Overactive Bladder
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
- Trial name
- NCT02656173
- Testing
- Mirabegron, Tamsulosin
- Where
- 58 sites in Japan, South Korea
- Volunteers
- 568 people
- Sponsor
- Astellas Pharma Inc